New drug cocktail aims to fight kidney cancer when immunotherapy fails

NCT ID NCT06835972

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two oral drugs, abemaciclib and cabozantinib, is safe and effective for people with advanced clear cell or translocation kidney cancer that has already been treated with immunotherapy. The trial has two phases: first, finding the best dose with minimal side effects (phase 1b), then measuring how often tumors shrink (phase 2). About 43 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib and cabozantinib (two oral drugs)
What this could lead to: If successful, this could offer a new treatment option for people with advanced kidney cancer whose disease has progressed after immunotherapy.
What could go wrong: This is an early-phase trial with only 43 participants, so results may not apply broadly. The drug combination may cause significant side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clear cell renal carcinoma MIT family translocation renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC RENAL CELL CARCINOMA TRANSLOCATION RENAL CELL CARCINOMA

Contacts and locations

Locations

Johns Hopkins University (Data Collection Only)
RECRUITING

Baltimore, Maryland, 21287, United States
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities)
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering West Harrison (Limited Protocol Activities)
RECRUITING

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.